Methotrexate, formerly known as amethopterin, is a chemotherapy agent and immune-system suppressant.
Facts
Drug ClassChemotherapy agent and immunosuppressant (antimetabolite) 1 Mechanism of ActionFunctions as an antimetabolite that inhibits dihydrofolate reductase (DHFR), blocking tetrahydrofolate synthesis and thereby DNA, RNA and thymidylate production; also suppresses T cells and interleukin-1 in autoimmune disease. 1 Approved UseTreats certain cancers and autoimmune conditions such as rheumatoid arthritis. 1 First Approved / Isolated Year Significant RiskNausea, fatigue, fever and increased infection risk with low white blood cell counts; serious effects may include liver disease, lung disease and lymphoma. 1 Classification
Approval Status ATC ClassSourced to the subject's own accountL: Antineoplastic and Immunomodulating Agents 2 Route of Administration WHO Essential MedicineSourced to the subject's own account Connections
Associated With
Treats
Source Methotrexate (Wikipedia)
Source Methotrexate (Wikipedia)
Sources
1. Methotrexate (Wikipedia)
Wikimedia FoundationLead section
a chemotherapy agent and immune-system suppressant
Infobox, drug class
Chemotherapy and immunosuppressant medication
Mechanism of action section
inhibits dihydrofolate reductase (DHFR)
History section
First synthesized in 1947; initial clinical use established in the early 1950s
Adverse effects section
Serious effects may include liver disease, lung disease, lymphoma
Lead section, route-of-administration statement
It can be given by mouth or by injection.
- Regulatory approval status
View the Source 2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code LQuote, First-level anatomical group codes, Code L
Antineoplastic and immunomodulating agents
View the Source 3. WHO Model List of Essential Medicines (Wikipedia)
WikipediaWHO Model List of Essential Medicines, Cytotoxic medicines sectionQuote, WHO Model List of Essential Medicines, Cytotoxic medicines section
Methotrexate
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.